TheraB Medical has been acquired by Natus Sensory, a global leader in sensory and newborn care solutions, to expand access to TheraB’s flagship product SnugLit – a wearable phototherapy device for neonatal jaundice designed in the form factor of an infant swaddle.
Snuglit, which received FDA 510(k) clearance in January 2026, is designed to deliver comprehensive body coverage while eliminating the need for eye protection required with traditional phototherapy. Critically for the family-centered care angle, its portable design allows continued parent interaction including bonding and breastfeeding during treatment – addressing a longstanding pain point where conventional phototherapy separates newborns from their mothers during a critical bonding window.
“TheraB was founded to advance effective jaundice treatment, and SnugLit was developed to preserve the critical bond between mother and baby,” said TheraB founder and SnugLit inventor Alexa Jones. “Joining Natus Sensory accelerates our path forward, expanding future access for clinicians, hospitals, and families who need it most.”
No financial terms were disclosed. TheraB was previously backed by angel investors and funds including Red Cedar Ventures, Healthcare Equity Angels, Michigan Rise, and Invest Detroit Ventures, among others. Natus Sensory, an ARCHIMED portfolio company, operates globally across hearing, balance, vision, and newborn care – giving SnugLit a significantly broader distribution footprint than TheraB could reach independently.
